Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Liquid Biopsy Biomarkers for Aggressive Prostate Cancer Discovered

By LabMedica International staff writers
Posted on 05 Jul 2016
Using targeted proteomics on noninvasive liquid biopsies, researchers have discovered biomarkers that provide signatures of aggressive (extracapsular) prostate cancer (PC), which could enable diagnosis before treatment and so help many low-risk PC patients avoid surgery.

Currently, needle biopsies are used to help diagnose PC, but this technique may not detect hidden tumors or cancer that has already spread beyond the organ. More...
The new research advances the quest to develop a precise, noninvasive diagnostic tool that can address over-treatment of slow-growing, low-risk PC.

"We believe we have found a better way that allows us to predict which patients have a slow-growing versus aggressive PC using non-invasive biomarkers. This could eventually help us personalize cancer treatment for these patients," said principal investigator Prof. Dr. Thomas Kislinger, of Princess Margaret Cancer Centre, University Health Network (UHN; Toronto, Canada), and of University of Toronto.

"A fluid-based biomarker would be ideal … to spare patients with indolent (slow-growing) disease from unnecessary procedures, while identifying and treating those who would benefit from treatment intensification," said co-lead author Dr. Yunee Kim.

The Kislinger team – in collaboration with Paul Boutros, Ontario Institute for Cancer Research (Canada), and O. John Semmes, Eastern Virginia Medical School (Norfolk, VA, USA) – used urine samples containing prostatic secretions from 210 patients after they had undergone digital rectal examinations (DRE, the standard clinical "first step" to determine need for further diagnostic testing of the prostate). The research took four years and involved samples from almost 300 patients.

"We used targeted proteomics to accurately quantify hundreds of proteins in urine samples (post-DRE) to identify liquid biopsy signatures. The first round of research involved 80 patients and quantified 150 proteins that were then narrowed down to 34 for further investigation. The next round involved a second, independent cohort of 210 patients,” said Dr. Kislinger, "Applying computational biology, we used the quantitative data from mass spectrometry to develop the fluid biomarkers for aggressive PC." He added, "The next step will be further studies with urine samples from 1,000 international patients to validate if the biomarkers identified have broader clinical utilities in PC."

The study, by Kim Y, Jeon J, et al, was published online ahead of print June 28, 2016, in the journal Nature Communications.

Related Links:
University Health Network



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.